Open Access

Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'‑deoxy‑3'‑[18F] fluorothymidine in patients with lung cancer

Corrigendum in: /10.3892/ol.2018.8756

  • Authors:
    • Xiangcheng Wang
    • Yulin He
    • Weina Zhou
    • Xia Bai
    • Yiwei Wu
    • Xuemei Wang
    • Xiao‑Feng Li
  • View Affiliations

  • Published online on: August 28, 2017     https://doi.org/10.3892/ol.2017.6840
  • Pages: 5279-5284
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In a mouse model of human lung cancer, intratumoral distribution between 3'‑deoxy‑3'‑[18F] fluorothymidine (18F‑FLT) and [18F] fluorodeoxyglucose (18F‑FDG) was mutually exclusive. 18F‑FLT primarily accumulated in proliferating cancer cells, whereas 18F‑FDG accumulated in hypoxic cancer cells. The aim of the present study was to evaluate these preclinical findings in patients with lung cancer. A total of 55 patients with solitary pulmonary lesion were included in the present study. Patients underwent 18F‑FLT positron emission tomography‑computed tomography (PET/CT) and 18F‑FDG PET/CT scan with a 3‑day interval. The final diagnosis was based on histological examination. Among the 55 cases, a total of 24 cases were confirmed as malignant lesions. Mismatched 18F‑FLT‑ and 18F‑FDG‑accumulated regions were observed in 19 cases (79%) and matched in 5 (21%). Among the 31 benign lesions, 18F‑FLT and 18F‑FDG were mismatched in 12 cases (39%) and matched in 19 (61%). The difference in intratumoral distribution of 18F‑FLT and 18F‑FDG between malignant and benign lesions was statistically significant (P<0.05). The results of the present study indicate that a mismatch in intratumoral distribution of 18F‑FLT and 18F‑FDG may be a feature of patients with lung cancer. Increased 18F‑FDG accumulation may serve as an indicator of tumor hypoxia, whereas regions with increased 18F‑FLT uptake may be associated with an increased rate of cancer cell proliferation in patients with lung cancer.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, He Y, Zhou W, Bai X, Wu Y, Wang X and Li XF: Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'‑deoxy‑3'‑[18F] fluorothymidine in patients with lung cancer Corrigendum in /10.3892/ol.2018.8756. Oncol Lett 14: 5279-5284, 2017
APA
Wang, X., He, Y., Zhou, W., Bai, X., Wu, Y., Wang, X., & Li, X. (2017). Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'‑deoxy‑3'‑[18F] fluorothymidine in patients with lung cancer Corrigendum in /10.3892/ol.2018.8756. Oncology Letters, 14, 5279-5284. https://doi.org/10.3892/ol.2017.6840
MLA
Wang, X., He, Y., Zhou, W., Bai, X., Wu, Y., Wang, X., Li, X."Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'‑deoxy‑3'‑[18F] fluorothymidine in patients with lung cancer Corrigendum in /10.3892/ol.2018.8756". Oncology Letters 14.5 (2017): 5279-5284.
Chicago
Wang, X., He, Y., Zhou, W., Bai, X., Wu, Y., Wang, X., Li, X."Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'‑deoxy‑3'‑[18F] fluorothymidine in patients with lung cancer Corrigendum in /10.3892/ol.2018.8756". Oncology Letters 14, no. 5 (2017): 5279-5284. https://doi.org/10.3892/ol.2017.6840